ArticleFrontiers in oncology2023

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT.

Zhangjie Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.